A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive
Arquivos de Neuro-Psiquiatria
Objective Natalizumab is a new and efficient treatment for multiple sclerosis (MS). The risk of developing progressive multifocal leukoencephalopathy (PML) during the use of this drug has created the need for better comprehension of JC virus (JCV) infection. The objective of the present study was to assess the prevalence of JCV-DNA in Brazilian patients using natalizumab. Method Qualitative detection of the JCV in the serum was performed with real-time polymerase chain reaction (PCR). Resultsdoi:10.1590/0004-282x20130121 pmid:24212514 fatcat:mfpixviblzdcpea77oc6ho4cou